NORTH
02 Dec 2020
Trial Summary
This is an open label, Phase II, multicentre study evaluating the anti-tumour activity of continuous, low dose of panobinostat in patients with refractory solid tumours stratified by primary histology into osteosarcoma, malignant rhabdoid tumour/atypical teratoid rabdoid tumour (MRT/ATRT) and neuroblastoma.
Acronym:
NORTH
ACTRN/NCT /ethics:
ACTRN12618000321246
Scientific title:
A phase II study study of panobinostat in paediatric, adolescent and young adult patients with solid tumours including osteosarcoma, malignant rhaboidntumour/ atypical teratoid rhabdoid tumours and neuroblastoma.
Sponsor / Cooperative group:
ANZCHOG
Trial & Patient Characteristics
| Cancer Type | Other |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | Under 40 years of age |
| Sex | Both |
| Tumour Stream | - |
| Cancer Stage | All stages |
| Anticipated Start Date | 2018-03-05 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Nimit Singhal |
| Recruitment Status | Recruiting |